Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study

Published:2019-04-01 Issue:6 Volume:83 Page:1083-1090
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Li Hui,Zeng Jian,Jin Xiangyu,Yu Xinmin,Zhou Guoming,Hong Wei^ORCID

Funder

Young Scientists Fund

Natural Science Foundation of Zhejiang Province

Zhejiang Provincial Key Laboratory of Wood Science and Technology

Zhejiang Province Public Welfare Technology Application Research Project

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-019-03823-4.pdf

Reference39 articles.

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132. https://doi.org/10.3322/caac.21338

2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96. https://doi.org/10.3322/CA.2007.0010

3. Simon GR, Turrisi A, American College of Chest P (2007) Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edn). Chest 132 (3 Suppl):324S–339S. https://doi.org/10.1378/chest.07-1385

4. Stratigos M, Matikas A, Voutsina A, Mavroudis D, Georgoulias V (2016) Targeting angiogenesis in small cell lung cancer. Transl Lung Cancer Res 5(4):389–400. https://doi.org/10.21037/tlcr.2016.08.04

5. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17(2):658–667. https://doi.org/10.1200/JCO.1999.17.2.658

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer;Cancer Medicine;2022-09-09

2. Personalized treatment of extensive stage small cell lung cancer: A case report and literature review;Frontiers in Oncology;2022-08-11

3. Signal pathways and precision therapy of small-cell lung cancer;Signal Transduction and Targeted Therapy;2022-06-15

4. A phase II study of anlotinib combined with etoposide and platinum‐based regimens in the first‐line treatment of extensive‐stage small cell lung cancer;Thoracic Cancer;2022-04-07

5. Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study;Clinical Medicine Insights: Oncology;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3